Gilead’s Q1 – The Numbers that Matter

  • Posted by on April 22nd, 2014 at 8:46 pm

 

Gilead ($GILD) smoked estimates (including mine) this evening with top and bottom line numbers that ripped Wall St. and Estimize forecasts. This graph is ridiculous.

Here’s the YoY breakdown:

  • Revenue +98%
  • Net income tripled
  • U.S. product sales +160%
  • Euro product sales +25%
  • Antiviral sales +119%
  • Cardiovascular sales +9%
  • Generated $1.57B in operating cash flow

And oh yeah, they finished Q1 with $6.86 billion in cash and equivs.

 

sources:  Y! Finance

Estimize